ArticleClinical ophthalmology (Auckland, N.Z.)2009
Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis.
Article in Clinical ophthalmology (Auckland, N.Z.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis.Medicine · 2019Pooled it
- Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews.Croatian medical journal · 2014Pooled it
- Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.BMC ophthalmology · 2022Trial
- Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.BMC ophthalmology · 2014Trial
- A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- There's Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma.Cureus · 2022Article
- Distribution ofOphthalmology and therapy · 2020Article
- A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients.Japanese journal of ophthalmology · 2020Article
- Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis.International journal of ophthalmology · 2020Article
- Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- Review
- Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients.Journal of ophthalmology · 2018Article
- Medical Management of Glaucoma in the 21st Century from a Canadian Perspective.Journal of ophthalmology · 2016Review
- Managing adverse effects of glaucoma medications.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
- Latanoprost in the treatment of glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
- Citation of previous meta-analyses on the same topic: a clue to perpetuation of incorrect methods?Ophthalmology · 2013Article
- Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2010Article
- Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2010Article
- Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.Drugs & aging · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy. The relative efficacy of differing prostaglandin therapy is disputed.
methodsA meta-analysis was conducted of head-to-head randomized trials of prostaglandin therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence margins.
resultsOur search identified 16 eligible trials, of which 15 were included in the meta-analysis. Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], -0.24 mmHg, 95% CI, -0.87 to 0.38, P = 0.45, I2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, I2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P </= 0.001, I2 = 97%, 95% CI, 95 to 98, P </= 0.001). Five trials assessing latanoprost and bimatoprost revealed an elevated risk of conjunctival hyperemia with bimatoprost (RR 1.59, 95% CI, 1.02 to 2.48, P = 0.04, I2 = 76%, 95% CI, 16 to 88, P = 0.002).
conclusionRandomized head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy effects, but differing hyperemia effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.